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Manuela Gridling,d Keiryn L. Bennett,d Jacques Colinge,d Walter Berger,e
Paul J. Dyson,f Giulio Superti-Furga,d Bernhard K. Kepplerb
and Christian G. Hartinger*a
The clinical development of anticancer metallodrugs is often hindered by the elusive nature of their
molecular targets. To identify the molecular targets of an antimetastatic ruthenium organometallic
complex based on 1,3,5-triaza-7-phosphaadamantane (RAPTA), we employed a chemical proteomic
approach. The approach combines the design of an aﬃnity probe featuring the pharmacophore with
mass-spectrometry-based analysis of interacting proteins found in cancer cell lysates. The comparison
of data sets obtained for cell lysates from cancer cells before and after treatment with a competitive
binder suggests that RAPTA interacts with a number of cancer-related proteins, which may be
responsible for the antiangiogenic and antimetastatic activity of RAPTA complexes. Notably, the proteins
identiﬁed include the cytokines midkine, pleiotrophin and ﬁbroblast growth factor-binding protein 3. We
also detected guanine nucleotide-binding protein-like 3 and FAM32A, which is in line with the
hypothesis that the antiproliferative activity of RAPTA compounds is due to induction of a G2/M arrest
and histone proteins identiﬁed earlier as potential targets.Introduction
The modes of action of organometallic anticancer ruthenium
complexes, which are substantially diﬀerent from commonly
used platinum-based chemotherapeutics, account for the
growing interest in this compound class.1–4 RAPTA complexes
are a promising class of organometallic RuII compounds which
inhibit processes related to metastasis in vitro and exhibit
pronounced antimetastatic activity in vivo, but only lowAuckland, Private Bag 92019, Auckland
ckland.ac.nz
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hemistry 2015antiproliferative activity.5,6 The general formula of RAPTA
compounds is [Ru(arene)(PTA)X2] (Fig. 1), where PTA ¼ 1,3,5-
triaza-7-phosphatricyclo-[3.3.1.1]decane and X ¼ halogenide or
biscarboxylate. With their cis-congured halogenido ligands
resembling the cisplatin structure, DNA was initially considered
to be the target.7,8 However, in recent years the focus of mode of
action studies has shied from investigations of RAPTA–DNA to
RAPTA–protein interactions.9–11 It has been demonstrated that
RAPTA compounds preferentially bind to proteins even in the
presence of DNA, as shown in crystallographic and bioanalytical
studies with the nucleosome core particle.12,13
Notably, the selection of the ligands determines the reac-
tivity of organoruthenium compounds with biological targets.Fig. 1 Schematic representation of the components of the RAPTA
framework.
Chem. Sci., 2015, 6, 2449–2456 | 2449
Fig. 2 Schematic representation of the work-ﬂow used in the met-
allodrug pull-down experiments. In the non-competitive pathway
(data set 1) proteins can bind only to modiﬁed beads, whereas in the
competitive pathway (data set 2) proteins can bind to modiﬁed beads
and competitive binder 3.
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View Article OnlineIn contrast to the RAPTA derivatives, Ru(arene) complexes with
a chelating ethylenediamine ligand bind preferentially to
DNA.13 In addition, adduct formation of RAPTA with a range of
isolated proteins has been demonstrated, and in some cases
enzyme inhibition has been observed.9–11,14–17 In comparison to
platinum compounds, RAPTA complexes tend to be more
reactive towards proteins, but also display greater selectivity,
even though both compound classes react with the same
binding sites in proteins.14
Molecular proling of the interactions of RAPTA compounds
with their cellular targets would help to improve our under-
standing of their modes of action. The screening of putative
RAPTA–protein interactions is laborious because of the enor-
mous number of potential biomolecular targets in cells. More-
over, additional complexity arises because of the reactivity of
metal complexes in aqueous systems due to hydrolysis. There is
also the possibility that non-selective binding to any nucleo-
philic amino acid side chain donor atomsmay occur. Therefore,
a test system that does not distort the actual system too much is
required, which, however, necessitates advanced analytical and
molecular biology approaches.18 Recently, Messori et al. and
Wolters et al. demonstrated the importance of using proteomic
studies in the evaluation of cancer cell responses to RAPTA-T,
[Ru(h6-toluene)(PTA)Cl2], treatment at the protein level.19,20
Wolters et al. employed multidimensional protein identica-
tion technology and identied 414 proteins out of which 74
proteins were further analyzed on their regulation prole,19 and
histones were suggested to play an important role in the mode
of action of RAPTA complexes.12 Messori et al. used 2-dimen-
sional diﬀerence gel electrophoresis to monitor the changes in
the expression of intracellular proteins upon exposure of cancer
cells to RAPTA-T. In comparison to the control experiment,
RAPTA-T did not induce signicant modications of protein
expression proles although a small number of up- and down-
regulated proteins were detected.20 It is worth noting that in
both cases substantial diﬀerences in the proteome proles of
cells treated with RAPTA compounds and those treated with
platinum complexes were observed, highlighting their diﬀerent
modes of action.
In this paper, we describe the development of a chemical
proteomic method (“drug pull-down”), involving aﬃnity chro-
matography, shotgun proteomics and bioinformatics, to iden-
tify molecular targets of an antimetastatic RAPTA anticancer
agent. To the best of our knowledge, such an approach is
unprecedented for metal-based anticancer agents. The solid-
phase functionalized with the RAPTA derivative was especially
designed for this purpose.
Results and discussion
The molecular targets of metallodrugs are oen elusive despite
intensive analytical and biochemical eﬀorts to identify them.
This problem may partially be ascribed to the reactivity of
metallodrugs in aqueous solution and the multitude of ligand
exchange reactions that may occur depending on pH and
concentrations of potential nucleophiles. Drug pull-down
experiments allow the molecular targets of drugs to be2450 | Chem. Sci., 2015, 6, 2449–2456identied. This approach has been applied to organic drugs;
however, to the best of our knowledge immobilizing an organ-
ometallic anticancer agent is unprecedented and requires
careful functionalization of the pharmacophore and selection
of the experimental conditions.Experimental design
In order to establish the ‘natural’ target prole of RAPTA anti-
cancer agents, we used a combination of drug aﬃnity chro-
matography with RAPTA-modied beads, subsequent high-end
mass spectrometry and bioinformatics. This approach is
termed drug pull-down and the work-ow is depicted in Fig. 2.21
The natural state and environment of proteins, e.g. abundance,
post-translational modications, natural binding partners, etc.
in the employed whole cell lysates are preserved.22
High-aﬃnity binders may be identied by comparing the two
routes of analysis, i.e., the non-competitive (data set 1) and
competitive route (data set 2; Fig. 2). To obtain data set 1 in a
non-competitive experiment, the beads loaded with the probe 2
are exposed to the cell lysate. In contrast, in the competitive
experiment, the probe is in competition with the free drug
analogue 3 for the preferred protein target. A signicant
reduction or even the complete disappearance of spectral
counts during competitive reactions indicate high-aﬃnity
binders.
The traditional drug pull-down experiment involves covalent
attachment of drug molecules or fragments to matrices such as
N-hydroxysuccinimidyl-sepharose and requires extensive
cleansing to block unreacted beads.22 Such cleansing is notThis journal is © The Royal Society of Chemistry 2015
Fig. 3 Molecular structures of 1 and 3 (one of two independent
molecules) shown at the 50% probability level. For bond lengths and
angles see ESI.†
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View Article Onlinepossible using reactive metallodrugs as they are likely to
undergo undesirable side reactions during the workow. To
avoid decomposition of the organometallic complex during
immobilization onto the matrix, we employed a biotin/strepta-
vidin approach, which draws on one of the largest known
binding constants of K  1014 M1 and has been used in bio-
catalysis.23 This self-assembly approach results in near quanti-
tative functionalization of the beads with the RAPTA moiety,
requiring minimal purication that could potentially deactivate
the complex.
Since the chlorido ligands bound to the RuII center of RAPTA
anticancer agents undergo hydrolysis and subsequent reaction
with nucleophiles to form coordinative bonds to biological
targets,9,10,12,16 the primary ligand sphere seems unsuitable for
immobilization onto beads. Therefore, the arene ligand was
functionalized with a primary amine and subsequently with
biotin via an aminocaproic acid linker to yield 2 (Fig. 2). This
compound was generated in situ and immobilized on strepta-
vidin-modied beads. In order to perform competition experi-
ments (competitive pathway in Fig. 2), 1 was converted into the
non-immobilized acetyl derivative 3.
The functionalized RAPTA complexes 1 and 3 were synthe-
sized using a similar procedure to one described in the litera-
ture24 by stirring PTA with the corresponding chlorido-bridged
dinuclear ruthenium precursor in dry DMF for 3–4 h. In order to
avoid undesirable coordination of the –NH2 group to the
ruthenium center upon addition of base, benzylamine was
chosen. It was reduced by Birch reduction and protonated prior
to complexation with RuCl3 to give the dinuclear precursor [(h
6-
benzylammonium)RuCl2]2 chloride. Subsequently, complex 2
was obtained by stirring 1 with biotin-6-aminohexanoic acid-N-
hydroxysuccinimide ester and triethylamine in dry DMF for
24 h. By employing 6-aminohexanoic acid as a linker, the
distance between streptavidin and the reactive metal center was
extended to allow suﬃcient exibility and low steric demand so
as not to impede reactions with target proteins. Functionalized
complexes 1 and 3were characterized by NMR spectroscopy, ESI
mass spectrometry and elemental analysis (see Experimental
section for full details). The presence of the functional groups
did not signicantly aﬀect the 31P{1H} chemical shi being
observed at31 ppm (cf.34.9 ppm for RAPTA-C,5 i.e., [Ru(h6-p-
cymene)(PTA)Cl2]). The signal corresponding to the protons in
the –NH3
+ group in 1 was detected at 8.39 ppm as a broad
singlet, whereas the NH signal in 3 appeared as a well-resolved
triplet at 8.30 ppm. Compound 2 was characterized in situ by
high resolution nESI-Q-TOF MS and the pseudomolecular mass
signal [M + H]+ was found with an accuracy of 5 ppm.
The molecular structures of 1 and 3 were established by
single crystal X-ray diﬀraction analysis (Fig. 3). Crystals were
grown by slow diﬀusion of diethyl ether into DMF at 277 K.
Analysis of the bond lengths and angles conrmed structural
similarity to RAPTA-C (Tables S1 and S2, ESI†).25 The distance
between the ruthenium center and the centroid of the arene is
similar among the three complexes (1.700, 1.699 and 1.692 A˚ for
1, 3 and RAPTA-C, respectively) indicating that methylamine
derivatization does not alter the electron density on the metal.
The Ru–P bond length (around 2.3 A˚) and the Ru–Cl bondThis journal is © The Royal Society of Chemistry 2015lengths in 1 and 3 range from 2.3966(4) to 2.4291(4) A˚ and are
similar to those in RAPTA-C (2.412(3) A˚ and 2.429(2) A˚), which
underlines the retained geometry of the rst coordination
sphere upon derivatization of the arene. P–Ru–Cl angles vary
between 82 and 87, which is also in agreement with RAPTA-C
(83–87). Furthermore, the Cl1–Ru–Cl2 angle is around 88 in
all complexes. This indicates that the RAPTA derivatives can be
used as suitable structural models for drug pull-down
experiments.
Immobilization of the pharmacophore and validation of its
properties
In order to demonstrate that the modied RAPTA probe retains
the chemical and biological properties of the parent RAPTA
compound, a series of experiments were performed to elucidate
the interactions with biomolecules.
Binding of biotin derivatives to streptavidin. Molecular
modeling was used to evaluate the binding ability of the func-
tionalized biotin into the target pocket of streptavidin. The
docking scaﬀold was based on a biotin/streptavidin crystal
structure (PDB 3RY2).26 The four scoring functions included in
the GOLD soware suite reproduced the experimental binding
conformation well with a low root-mean-square deviation (e.g.
goldscore (GS) gave 0.30 A˚). In a second step, the ligand without
the metal moiety was used as a model system, followed by
addition of the Ru–PTA fragment to the functionalized arene.
GS was the only scoring function able to treat the metal frag-
ment. The biotin moieties of all the docked compounds showed
good overlap with the co-crystallized biotin, reproducing also
the hydrogen bonding pattern. The best scoring GS values of
82.0 for the organic fragment and 75.7 for 2 indicate that the
binding energy of all the molecules is similar or slightly higher
than that of biotin (70.7). Moreover, comparing a variety of
highly scoring docking congurations indicates that the
ruthenium moiety is exible and accessible on the protein
surface and the biotin scaﬀold is stable in the binding pocket
(Fig. S1†).
Binding of the functionalized pharmacophore to proteins.
The ruthenium drug candidate is supposed to interact with
proteins in the lysis mixture through a ligand substitution
process involving the loss of the chlorido ligands via hydrolysis
and subsequent coordination of nucleophilic donors to theChem. Sci., 2015, 6, 2449–2456 | 2451
Fig. 4 Deconvoluted nESI-Q-TOF mass spectra of ubiquitin (8564.64
Da) and after incubation with 1 or 3 for 24 h. The mixture was incu-
bated at a 2 : 1 metal-to-protein ratio in tetramethylammonium
acetate.
Table 1 In vitro anticancer activity of compounds 1–3 and RAPTA-C in
the human cancer cell lines CH1, SW480 and A549 after 96 h
incubation
Compound
IC50/mM
CH1 SW480 A549
1 9.6  1.2 358  19 >500
2 74  6 216  81 >500
3 13  1 357  79 >500
RAPTA-C 65  15 170  60 >500
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View Article Onlinemetal center. While it is generally believed that the key activa-
tion step of RuII organometallics in the cell is hydrolysis, direct
reaction is possible, although much slower.27 The binding
properties of 1 and 3 towards small proteins were investigated
in order to test their tendency to form adducts with model
proteins. Both compounds were incubated with ubiquitin (ub)
and cytochrome c (cyt) in water (pH 5.5) and tetramethylam-
monium acetate buﬀer (pH 8.0) for 30 min up to 24 h in order to
compare the inuence of the pH on the reactivity of the RAPTA
derivatives (Fig. 4, 5, S2 and S3†). Compounds 1 and 3 were
characterized by negligible adduct formation within 24 h in
buﬀered solution, whereas in aqueous solution the reactivity of
the organometallic complexes toward biomolecules was
enhanced. In other words, the relative abundance of the
combined ubiquitin adducts increased from nearly zero in basic
milieu to 18% and 13% for 1 and 3, respectively, in slightly
acidic milieu.
The compounds form diﬀerent low-abundance adducts, e.g.
the [Ru(arene)(PTA)] fragment coordinated to ubiquitin in the
case of 3 (ESI†). From these experiments, it is evident that the
main form of interaction between the RAPTA derivatives and
model proteins occurs via the substitution of the chlorido
ligands. It should be noted that 1 contains a free amine that isFig. 5 Deconvoluted nESI-Q-TOF mass spectra of ubiquitin (8564.64
Da) and after incubation with 1 or 3 for 48 h. The mixture was incu-
bated at a 2 : 1 metal-to-protein ratio in water.
2452 | Chem. Sci., 2015, 6, 2449–2456charged at physiological pH, which is not the case for 2 or 3. The
adduct types and abundances are similar independent of the
arene substituent in case of ubiquitin (Fig. 4 and 5). Compound
1 containing the ammonium moiety on the arene is more
reactive in the presence of the redox active cytochrome c and the
adducts are mainly characterized by arene loss in slightly acidic
milieu. Here, the relative abundance of the adducts are 36% and
24% for 1 and 3, respectively, in acidic milieu. In basic milieu,
only 1 forms a monoadduct (22% relative abundance). It seems
that the benzylammonium arene is slightly less stable than the
acetylated analogue. However, the general reactivity of the
RAPTA derivatives towards model proteins is therefore retained,
although slightly lower compared to that of RAPTA-C.10
Cytotoxicity. A suitable cell line for the metallodrug pull-
down assay was chosen based on cytotoxicity studies (Table 1,
Fig. S4†). Ideally, the functionalized derivative to be immobi-
lized should show a similar activity prole as the parent
compound. Therefore, the eﬃcacy of 1–3 to inhibit cancer cell
growth in the ovarian cancer CH1, colon carcinoma SW480 and
non-small cell lung cancer A549 cell lines was tested by using
the MTT assay (Table 1) and compared to that of RAPTA-C as the
parent drug candidate. In the case of the RAPTA derivatives
tested, the compounds were inactive in the chemoresistant
A549 cell line and displayed low activity against SW480 cells. In
the CH1 cell line, however, the compounds showed reasonable
cytotoxicity and compound 2 featured a very similar activity
prole to RAPTA-C. The CH1 cell line was therefore chosen for
the metallodrug pull-down experiments as these cell lysates are
most likely to yield detectable drug–target adducts and may
allow drawing conclusions also with respect to their metastatic
potential.Drug pull-down experiments
Based on these ndings, the complex was prepared in situ and
incubated with streptavidin beads (30 min, 4 C). The bead
slurry was centrifuged and washed with lysis buﬀer. DMSO,
which is typically used for the reaction of organic molecules in
pull-down experiments with beads, turned out to be detrimental
for the immobilization of the metallodrug and was replaced by
DMF. Incubation of 1 and 3 in DMSO resulted in partial loss of
the arene moiety as evidenced by ESI-MS and 1H NMR spec-
troscopy stability experiments (Fig. 6, S5 and S6†). Upon incu-
bation of 1 in DMSO-d6 for more than 3 h, a new set of signals
was detected in the 1H NMR spectrum in the aromatic regionThis journal is © The Royal Society of Chemistry 2015
Fig. 6 ESI-ITmass spectra of 1 in DMSO. The solution was diluted with
water–methanol (1 : 1) prior to injection into the mass spectrometer.
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View Article Online(around 7.4–7.5 ppm) indicating the release of the arene
(Fig. S6†). Aer 24 h, the intensity of these signals signicantly
increased and a second set of peaks in the PTA region was
detected. These observations were conrmed by ESI-ion trap
MS. Aer 3 h the mass signals corresponding to 1 completely
disappeared and a new signal atm/z 527.81 was detected, which
may be assigned to [Ru(DMSO)3(OH)2(PTA) + H]
+ (Fig. 6 and
S5†). It should be noted that the p-cymene ring in RAPTA-C is
considerably more stable under similar conditions.
In DMF, however, the arene moiety of the RAPTA complex
was suﬃciently stable for at least 24 h (Fig. S7†). Therefore, the
incubation of the probe was conducted in DMF (Fig. 2). Addi-
tionally, the behavior of complexes 1–3 in water (Fig. S8–S11†)
was assayed by ESI-MS, which conrmed their stability during
the washing steps of the drug pull-down experiments. However,
even partial arene cleavage should not yield false positive data,
as 3 as the competitive binder behaves very similarly to 2.
The incubation of the probe was followed by centrifugation,
an additional washing step and subsequent incubation of the
beads with CH1 lysates rather than treating live cells with the
biotin-functionalized pharmacophore. This circumvents issues
that may be arising by adding the biotin group to a smallTable 2 List of cancer-related proteins identiﬁed by chemical proteomi
Protein type Gene Name
Extracellular growth factor MK_HUMAN Midkine
PTN_HUMAN Pleiotrophin
FGFP3_HUMAN Fibroblast growth fa
Cell cycle-regulating GNL3_HUMAN Guanine nucleotide-
FA32A_HUMAN Protein FAM32A
VIR_HUMAN Protein virilizer hom
CGBP1_HUMAN CGG triplet repeat-bi
Histone-related H31_HUMAN Histone H3.1
FBRL_HUMAN rRNA 20-O-methyltran
CGBP1_HUMAN CGG triplet repeat-bi
Ribosomal RS20_HUMAN 40S ribosomal protei
RRP1B_HUMAN Ribosomal RNA proc
protein 1 homolog B
a The numbers indicate the spectral counts. b Decrease of spectral counts
This journal is © The Royal Society of Chemistry 2015molecule and therefore changing the biological properties of
the pharmacophore, including the uptake and distribution in
the cell. This may lead to accumulation in cell compartments
diﬀerent to the original drug, which would impact the analysis.
Aer centrifugation, the beads were washed with lysis buﬀer
and HEPES, respectively. High chloride concentrations, as in
the lysis buﬀer, are known to slow down any ligand exchange
reactions of RAPTA compounds and should preserve the phar-
macophore in the desired form.28,29 To elute bound proteins,
beads were treated with elution buﬀer (50% urea, 50% formic
acid). All eluates were separated by on-line HPLC and analyzed
by MS. The acquired raw MS data les were converted into
Mascot generic format (mgf) les and the resultant peak lists
were searched against the human SwissProt database. Identi-
ed and validated proteins were merged and grouped according
to shared peptides (see Experimental section).
Bioinformatic analysis of the datasets obtained from drug
pull-down experiments resulted in the identication of a total of
184 proteins. To reduce the signal-to-noise ratio without
reducing the sensitivity of the pull-down protocol, competition
experiments with the acetylated RAPTA analogue 3, which
mimics the conjugated complex 1, were included in the work-
ow. For competition experiments, cell lysates were pre-incu-
bated with 3 before incubation with the aﬃnity matrix. Complex
3 and immobilized 2 compete for the same set of proteins.
When analyzed by MS, this results in a signicantly reduced
abundance of high-aﬃnity binders and their interactors in the
puried sample. When the two independent data sets are
compared, the complete disappearance of the targets or a
signicant reduction of the MS spectral counts (i.e., the number
of mass spectra recorded for a peptide) for the competitive pull-
down, is suggestive of binding. This method is sensitive and
reliable with the limitation that high-abundance proteins could
also be targets of the drug.30 A threshold of at least 2-fold
increase in spectral counts from competitive to regular pull-
down was considered to be signicant (Tables 2 and S3†) and 29
of 184 proteins (16%) successfully fullled this criterion. Incs
Drug pull-down
(data set 1)a
Competition
experiment (data set 2)a
6 2
5 3b
ctor-binding protein 3 2 0
binding protein-like 3 2 0
4 0
olog 3 0
nding protein 1 2 0
4 1
sferase brillarin 2 0
nding protein 1 2 0
n S20 2 0
essing 4 1
by a factor of 1.5.
Chem. Sci., 2015, 6, 2449–2456 | 2453
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View Article Onlinegeneral, the spectral counts for the enriched proteins were low
compared to the overall counts and sequence coverage for those
was less than 10% in most cases.Pull-down data analysis
A signicant amount of the 184 proteins identied in total
comprised ribosomal proteins (18) and zinc nger proteins (16),
which are “frequent hitters”, i.e. high-abundance proteins
frequently observed in pull-down experiments. Notably,
comparison of the dataset with that of the competition experi-
ment eliminated most of them and only 5 ribosomal proteins
and 2 zinc nger proteins were target proteins for RAPTA.
Interestingly, several proteins identied in the MudPIT analysis
by Wolters et al. (e.g., mitochondrial ATP synthase subunit O
(ATPO), stress-70 protein (GRP75), myosin light chain 6B
(MYL6B)) and heat shock proteins were also observed in our
drug pull-down experiments.19 However, they were considered
non-specic targets of RAPTA complexes, since the number of
spectral counts did not decrease during competitive experi-
ments. Out of the 29 enriched proteins, 15 proteins were found
to be cancer-related (see Table 2). We analyzed the subcellular
localization and biological function of these proteins (Table
S4†). According to the UniProtKB database, these proteins are
localized in the nucleus, cytoplasm, particulate fraction and
extracellular region. Such widespread localization of proteins is
in agreement with the results of subcellular fractionation
experiments of the parent compound and indicates the
dynamics of intracellular processes.19 These proteins may be
specic targets of RAPTA complexes and may explain their in
vitro antimetastatic properties as well as other eﬀects such as
the inhibition of angiogenesis.
Extracellular proteins. The in vitro and in vivo antimetastatic
properties of RAPTA complexes might be related to extracellular
eﬀects,31 and extracellular growth factors were also identied in
this study. Three of them, i.e., midkine (MK), pleiotrophin
(PTN) and broblast growth factor-binding protein 3 (FGFP3),
are heparin-binding proteins. MK and PTN are structurally
related low molecular weight proteins, which belong to a family
of secreted growth/diﬀerentiation cytokines.32–34 MK and PTN
are over-expressed in some malignant tumors and inuence
angiogenesis, cell growth, migration and/or survival.35 Interac-
tion with MK and PTN by RAPTA complexes may be related to
the increased activity of the complexes in highly invasive cell
lines,31 as well as their ability to reduce metastatic growth5 and
suppress angiogenesis.36 FGFP3 overexpression was reported to
trigger signicant increase in vascular permeability.37 The
antiangiogenic activity of RAPTA complexes may be related to
FGFP3 interference.
Cell cycle-regulating proteins. Among the enriched cancer-
related proteins was guanine nucleotide-binding protein-like 3
(GNL3). It is believed that this protein is required for the
maintenance of the proliferative capacity of cancer cells.38 GNL3
stabilizes MDM2 which is a TP53 suppressor. As p53 controls
cell cycle checkpoints and it was shown that RAPTA-C was
capable of inducing G2/M phase arrest of the cell cycle by up-
regulation of p53,39 this supports GNL3 involvement. This2454 | Chem. Sci., 2015, 6, 2449–2456observation is also consistent with the targeting of virilizer
homolog (VIR) and CGG triplet repeat-binding protein 1
(CGBP1), whose depletion results in reduction of cell prolifer-
ation and impact on the cell cycle distribution.40,41 CGBP1 serves
several functions in the development of cancer, including
participation in heat shock stress response.42,43 The function of
another detected protein, FAM32A is not yet clearly understood;
however, it was reported that this protein may possibly induce
G2 arrest and apoptosis.44
Histone-related proteins. The preference of RAPTA
complexes toward histones has been reported based on exper-
iments employing MudPIT and label-free protein quantica-
tion,19 SEC-ICP-MS and X-ray diﬀraction with a nucleosome core
particle.13,45 It is reasonable to suggest the signicance of
histones in the mode of action of RAPTA anticancer agents.
Histone modications induce global and local changes in the
organization of chromatin structure, which are associated with
oncogenesis.46 Targeting histones and histone-related proteins
by RAPTA complexes may result in the disruption of DNA
binding and transcription processes. Notably, histone H3.1
(H31) and rRNA 20-O-methyltransferase brillarin (FBRL), which
mediates methylation of Gln-105 of histone H2A, were among
the protein hits of the drug pull-down experiment. It should be
noted that chromatin-associated protein CGBP1 (see above)
exerts its activity by controlling histone modications.41
Ribosomal proteins. Ribosomal proteins (RP), which are
essential for protein synthesis and therefore highly abundant in
cells, might belong in the drug pull-down experiment to the
group of frequent hitters. It comprises low-specicity proteins
oen observed in such studies. However, such proteins might
also be potential targets of RAPTA anticancer agents. Ribosomal
proteins serve various functions in addition to protein biosyn-
thesis, including DNA replication, transcription and repair,
regulation of cell growth, proliferation and apoptosis.47 The 40S
ribosomal protein S20 (RS20), which was detected in the pull-
down approach, plays a role in the regulation of apoptosis.47
Another cancer-related protein of ribosomal origin identied
was ribosomal RNA processing protein 1 homolog B.
Summary and conclusions
Identication of cellular target proteins is a major challenge in
drug development. With the exception of DNA targeting
complexes the cellular targets of metal-based anticancer agents
are widely unknown. Since RAPTA complexes are at the fore-
front of medicinal, organometallic chemistry, an understanding
of their targets would facilitate further drug development.
RAPTA compounds are able to interact with a wide range of
diﬀerent proteins, as expected from a relatively simple metal
complex, undergoing ligand exchange reactions with nucleo-
philic amino acid donor atoms such as glutamate, lysine and
histidine.12 This broad action is, nonetheless, important, as it
may lead to a widespread modication of cellular proteins with
eﬀects on resistance and sensitizing phenomena. To learn more
about the cellular targets of RAPTA compounds we developed a
metallodrug pull-down assay to prole their molecular targets.
For this purpose, a RAPTA-analogue suitable for immobilizationThis journal is © The Royal Society of Chemistry 2015
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View Article Onlineon streptavidin beads was prepared by attaching biotin via a
linker to the coordinated h6-arene. The immobilized metal-
lodrug-analogue was exposed to cancer cell lysates, and the
metal-binding proteins were identied by high resolution MS.
Using this method 15 cancer-related proteins were identied
which can be associated with the observed antimetastatic,
antiangiogenic and antiproliferative activity of RAPTA agents. In
particular, MK, PTN and FGF3 are angiogenesis and metastasis-
related eﬀectors. We were also able to identify proteins related
to cell cycle regulation, i.e. GNL3, CGBP1, FAM32A and VIR.
Some of the hits are proteins that have been proposed earlier as
potential targets in complementary experiments, such as
histone proteins, conrming the suitability of the approach.
This methodology has broad applicability beyond RAPTA
complexes and enables, for the rst time, the direct identica-
tion of intracellular interactions of metallodrugs with proteins.
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